海南封关带火鹭燕医药股价，鹭燕医药海南地区收入不到3%

Core Insights - Lu Yan Pharmaceutical's stock price has surged, attributed to the "Hainan Free Trade Zone" initiative, with a cumulative increase of over 100% since December 2025 [1] - The company has increased its registered capital in its subsidiary in Hainan from 35 million to 100 million yuan to support business development and the establishment of a headquarters project [1] Financial Performance - In the first half of 2025, the company reported total revenue of 10.4 billion yuan, a year-on-year increase of 0.91% [2] - The net profit attributable to shareholders decreased by 18.83% to 155 million yuan [2] - Revenue from Fujian province accounted for approximately 72.76% of total revenue, amounting to 7.276 billion yuan, followed by Sichuan and Jiangxi provinces with revenues of 1.801 billion yuan and 999.2 million yuan, representing 17.32% and 9.54% of total revenue respectively [2] - Other provinces contributed only 330 million yuan, making up 3.18% of total revenue [2]